This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Are Medical Stocks Lagging Adagene (ADAG) This Year?
by Zacks Equity Research
Here is how Adagene Inc. Sponsored ADR (ADAG) and Alcon (ALC) have performed compared to their sector so far this year.
Philips (PHG) Drives Health Care Prospects With New Solutions
by Zacks Equity Research
Philips (PHG) announces Philips Virtual Care Management solutions, which provide a comprehensive approach to telehealth for patients, providers and payers.
Encompass Health (EHC) Opens JV Hospital for Oklahoma Patients
by Zacks Equity Research
Encompass Health (EHC) inaugurated the Owasso-based Ascension St. John Rehabilitation Hospital, that it will operate jointly with Ascension St. John to offer rehabilitative care in Oklahoma.
Here's Why You Should Retain Elevance (ELV) in Your Portfolio
by Zacks Equity Research
Strong local presence, improving top line, membership hike and significant new contracts in its government business poise Elevance Health (ELV) well for growth.
ALC vs. ISRG: Which Stock Is the Better Value Option?
by Zacks Equity Research
ALC vs. ISRG: Which Stock Is the Better Value Option?
Here's Why You Should Retain McKesson (MCK) Stock Right Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.
Reasons to Retain ShockWave Medical (SWAV) in Your Portfolio
by Zacks Equity Research
ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.
Acadia Healthcare (ACHC) to Build Behavioral Health Unit in Mesa
by Zacks Equity Research
Acadia Healthcare (ACHC) begins the construction of its Mesa-based behavioral health hospital to address the inadequacy of behavioral healthcare resources in Arizona.
Is Addus HomeCare (ADUS) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Addus HomeCare (ADUS) and Alcon (ALC) have performed compared to their sector so far this year.
Alcon (ALC) Unveils Expansive Vision Care Products at SECO 2023
by Zacks Equity Research
Alcon (ALC) showcases its reusable toric lens and dry eye/ocular health offerings at the SECO International Meeting 2023 in Atlanta.
ALC vs. ISRG: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ALC vs. ISRG: Which Stock Is the Better Value Option?
Alcon (ALC) Q4 Earnings Match Estimates, Margins Contract
by Zacks Equity Research
Alcon (ALC) reports impressive CER growth in net sales across all segments in the fourth quarter amid a challenging macroeconomic environment.
Top Stock Reports for Costco Wholesale, Intuit & Schlumberger
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Costco Wholesale Corporation (COST), Intuit Inc. (INTU) and Schlumberger Limited (SLB).
Alcon (ALC) Gains From Innovation, Faces FX Challenges
by Zacks Equity Research
Alcon's (ALC) Surgical franchise continues to lead the market with its portfolio of advanced technology, intraocular lenses, a substantial installed base of equipment and a growing consumable base.
Alcon's (ALC) Latest Buyout to Enhance Its Product Portfolio
by Zacks Equity Research
Alcon's (ALC) ophthalmic pharmaceutical product suite is expected to be significantly boosted by adding new products following the recent acquisition.
Alcon (ALC) Q3 Earnings Surpass Estimates, Sales Guidance Cut
by Zacks Equity Research
Alcon's (ALC) robust innovation pipeline is delivering solid results as evidenced by the strength in its comprehensive portfolio of PCIOLs, including PanOptix and Vivity.
Alcon (ALC) Clareon Suite to Get a Boost With Product Launch
by Zacks Equity Research
With the latest launch of Clareon Toric, Alcon's (ALC) Clareon Collection of IOLs is complete in the United States.
Alcon (ALC) Faces Cost Pressure, Supply Chain Disruption
by Zacks Equity Research
Given the supply chain challenges, unfavorable foreign exchange impact and inflationary pressure, Alcon (ALC) reduces its core EPS and net sales expectations for 2022.
Aerie (AERI) Rallies 205.6% in the Past Three Months: Here's Why
by Zacks Equity Research
Aerie (AERI) shares have skyrocketed in the past three months after the company announced its definitive agreement with Alcon, wherein the latter will acquire the former for $770 million.
Aerie (AERI) to be Acquired by Alcon for $770M, Shares Up
by Zacks Equity Research
Aerie (AERI) enters into an agreement with Alcon to be acquired for $770 million. Shares gain.
Alcon (ALC) Q2 Earnings Surpass Estimates, Guidance Lowered
by Zacks Equity Research
Alcon's (ALC) robust innovation pipeline is delivering solid results as evidenced by the successful launch of new ATIOL roles and SiHy contact lenses.
Cigna (CI) to Announce Q2 Earnings: Here's What to Expect
by Zacks Equity Research
Cigna's (CI) second-quarter results are likely to reflect higher pharmacy revenues and a growing customer base.
DraftKings (DKNG) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
DraftKings' (DKNG) second-quarter 2022 performance is likely to have benefited from the robust demand for mobile sports betting and expansion efforts in new states.
What Awaits Warner Bros. Discovery (WBD) in Q2 Earnings?
by Zacks Equity Research
Warner Bros. Discovery's (WBD) Q2 results are expected to reflect benefits from a solid content portfolio and slow yet steady advertising revenues.
NortonLifeLock (NLOK) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Though the heightened IT security demand amid the hybrid work environment is likely to have benefited NortonLifeLock's (NLOK) Q1 performance, forex headwinds might have hurt sales and earnings growth.